Keyphrases
Rheumatoid Arthritis
100%
High Density
100%
Drug Effects
100%
Drug Therapy
100%
Cholesterol Efflux Capacity
100%
High-density Lipoprotein Cholesterol (HDL-C)
36%
Tocilizumab
36%
Rheumatoid Arthritis Treatment
27%
Methotrexate
27%
Erythrocyte Sedimentation Rate
27%
Disease Activity Score 28 (DAS28)
27%
Adalimumab
27%
Inflammation
18%
Serum Samples
18%
Disease Activity
18%
Coronary Artery Disease
9%
Coronary Risk Factors
9%
New Drugs
9%
Treatment Efficacy
9%
Treatment Toxicity
9%
Clinical Information
9%
Cellular Cholesterol
9%
Paired Serum
9%
Starting Treatment
9%
Non-rheumatoid
9%
Fluorometric Assay
9%
THP-1 Macrophages
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Rheumatoid Arthritis
100%
Effusion
100%
Tocilizumab
36%
High Density Lipoprotein
27%
Methotrexate
27%
Adalimumab
27%
Disease Activity Score
27%
Inflammation
18%
Ischemic Heart Disease
18%
Disease Activity
18%
High Density Lipoprotein Cholesterol
9%
Combination Therapy
9%
Immunology and Microbiology
Inflammatory Arthritis
100%
Tocilizumab
44%
Methotrexate
33%
Erythrocyte Sedimentation Rate
33%
Adalimumab
33%
Macrophage
11%